The microbubble contrast agent bears a covalently coupled peptide and is designed to selectively bind alphavbeta3 integrin on the vascular endothelial surface. Alphavbeta3 integrin is a biomarker of angiogenesis expressed on activated blood vessels.
Targeson said the contrast agent could be useful for investigating the cellular and molecular mechanisms of angiogenesis, molecular imaging of alphavbeta3 integrin expression, and evaluating anticancer therapies.
Targeson debuts US contrast agent, August 11, 2009
Copyright © 2009 AuntMinnie.com